Literature DB >> 12067775

Clinical applications for change-point analysis of herpes zoster pain.

Renee A Desmond1, Heidi L Weiss, Ramin B Arani, Seng-jaw Soong, Martin J Wood, Paul A Fiddian, John W Gnann, Richard J Whitley.   

Abstract

Pain is the most frequent and disabling complication of herpes zoster. The analysis of pain severity data is complicated by the nonlinear rate of resolution. Further, three distinct phases characterize pain resolution--acute, subacute, and chronic. Using two clinical trial datasets as the bases for analyses, the rates of baseline pain resolution were computed across each of three phases and compared for age, severity of pain at onset, and number of lesions at baseline. The results defined transition points of 24.4 +/- 3.34 for the subacute phase and 110.3 +/- 11.9 days for the chronic phase. The model demonstrated a treatment effect of valiciclovir (VACV) during the subacute phase as compared to acyclovir (ACV) (P = 0.006) and supports effects of age, baseline pain and number lesions on pain cessation rates in the acute phase. This model verifies three phases of zoster pain and delineates the impact of treatment and other factors on the phase-specific rates of pain cessation.

Entities:  

Mesh:

Year:  2002        PMID: 12067775     DOI: 10.1016/s0885-3924(02)00393-7

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  12 in total

Review 1.  Treatment of herpes zoster and postherpetic neuralgia.

Authors:  Robert W Johnson; Robert H Dworkin
Journal:  BMJ       Date:  2003-04-05

2.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 3.  Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.

Authors:  Alexander K Schuster; Björn C Harder; Frank C Schlichtenbrede; Marc N Jarczok; Jonas Tesarz
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

4.  A Semiparametric Change-Point Regression Model for Longitudinal Observations.

Authors:  Haipeng Xing; Zhiliang Ying
Journal:  J Am Stat Assoc       Date:  2012-12-01       Impact factor: 5.033

5.  Natural history of pain following herpes zoster.

Authors:  Hans Gustav Thyregod; Michael C Rowbotham; Michelle Peters; Jessica Possehn; Marlene Berro; Karin Lottrup Petersen
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

Review 6.  Postherpetic neuralgia: from preclinical models to the clinic.

Authors:  Ada Delaney; Lesley A Colvin; Marie T Fallon; Robert G Dalziel; Rory Mitchell; Susan M Fleetwood-Walker
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

7.  Prevention of post-herpetic neuralgia using transcutaneous electrical nerve stimulation.

Authors:  Aleksander Stepanović; Marko Kolšek; Janko Kersnik; Vanja Erčulj
Journal:  Wien Klin Wochenschr       Date:  2014-12-04       Impact factor: 2.275

Review 8.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

9.  The PINE study: rationale and design of a randomised comparison of epidural injection of local anaesthetics and steroids versus care-as-usual to prevent postherpetic neuralgia in the elderly [ISRCTN32866390].

Authors:  Wim Opstelten; Albert JM Van Wijck; Gerrit A Van Essen; Erik Buskens; Annette AA Bak; Cornelis J Kalkman; Theo JM Verheij; Karel GM Moons
Journal:  BMC Anesthesiol       Date:  2004-01-26       Impact factor: 2.217

10.  Usefulness of Inflammatory Markers for the Prediction of Postherpetic Neuralgia in Patients with Acute Herpes Zoster.

Authors:  Jun Young Kim; Gyeong-Hun Park; Min Ji Kim; Hyun Bo Sim; Weon Ju Lee; Seok-Jong Lee; Shin-Woo Kim; Young Hoon Jeon; Yong Hyun Jang; Do Won Kim
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.